Table 3.

 Odds ratio (OR with 95% confidence interval (CI)) for progression of intestinal metaplasia (IM) according to Helicobacter pylori treatment and/or final H pylori status

	IM deterioration	No IM deterioration	OR (95% CI)	p Value
OAC group	104 (45.2%)	116 (56.6%)	0.63 (0.43–0.93)	0.018
Placebo group	126 (54.8%)	89 (43.4%)	1.0 (referent)
OAC+HP−ve	68 (37.6%)	96 (55.5%)	0.48 (0.32–0.74)	<0.001
Placebo+Hp+ve	113 (62.4%)	77 (44.5%)	1.0 (referent)
Hp+ve at 5 y	146 (65.8%)	97 (47.3%)	2.14 (1.45–3.16)	<0.001
Hp−ve at 5 y	76 (34.2%)	108 (52.7%)	1.0 (referent)

Hp+ve, H pylori infected; Hp−ve, H pylori negative.

OAC, omeprazole, amoxicillin, and clarithromycin.